Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab long-term extension in juvenile psoriatic arthritis and enthesitis-related arthritis
2018-002521-30Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of secukinumab in juvenile idiopathic arthritis (JIA) and juvenile idiopathic arthritis, enthesitis-related (JIA-ERA), sponsored by Novartis. Primary endpoint: JIA ACR30 response. Started Jan 2019; status: completed.
02
Drugs
secukinumab
03
Conditions
juvenile idiopathic arthritis (JIA)juvenile idiopathic arthritis, enthesitis-related (JIA-ERA)
Beyond the preview
Go deeper on 2018-002521-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002521-30.